DSM Capital Partners LLC Has $71.74 Million Position in Thermo Fisher Scientific Inc. (NYSE:TMO)

DSM Capital Partners LLC reduced its holdings in Thermo Fisher Scientific Inc. (NYSE:TMOFree Report) by 4.7% during the 4th quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm owned 135,161 shares of the medical research company’s stock after selling 6,626 shares during the period. Thermo Fisher Scientific makes up about 1.1% of DSM Capital Partners LLC’s investment portfolio, making the stock its 24th biggest position. DSM Capital Partners LLC’s holdings in Thermo Fisher Scientific were worth $71,742,000 at the end of the most recent quarter.

Several other hedge funds also recently bought and sold shares of TMO. Norges Bank acquired a new stake in Thermo Fisher Scientific in the fourth quarter worth $2,909,524,000. International Assets Investment Management LLC raised its holdings in shares of Thermo Fisher Scientific by 61,995.4% during the fourth quarter. International Assets Investment Management LLC now owns 1,009,671 shares of the medical research company’s stock worth $535,923,000 after acquiring an additional 1,008,045 shares during the period. Loomis Sayles & Co. L P raised its holdings in shares of Thermo Fisher Scientific by 17,046.7% during the third quarter. Loomis Sayles & Co. L P now owns 973,591 shares of the medical research company’s stock worth $492,803,000 after acquiring an additional 967,913 shares during the period. Clearbridge Investments LLC raised its holdings in shares of Thermo Fisher Scientific by 33.1% during the fourth quarter. Clearbridge Investments LLC now owns 2,228,730 shares of the medical research company’s stock worth $1,182,987,000 after acquiring an additional 553,695 shares during the period. Finally, Franklin Resources Inc. raised its holdings in shares of Thermo Fisher Scientific by 16.0% during the fourth quarter. Franklin Resources Inc. now owns 2,518,760 shares of the medical research company’s stock worth $1,336,933,000 after acquiring an additional 347,560 shares during the period. 89.23% of the stock is currently owned by institutional investors and hedge funds.

Insiders Place Their Bets

In related news, SVP Michael A. Boxer sold 2,000 shares of the business’s stock in a transaction that occurred on Friday, April 26th. The stock was sold at an average price of $567.94, for a total value of $1,135,880.00. Following the completion of the sale, the senior vice president now directly owns 13,083 shares in the company, valued at $7,430,359.02. The sale was disclosed in a filing with the SEC, which is available at this link. In other news, CEO Marc N. Casper sold 10,000 shares of the business’s stock in a transaction that occurred on Tuesday, March 12th. The shares were sold at an average price of $597.98, for a total value of $5,979,800.00. Following the completion of the transaction, the chief executive officer now directly owns 123,816 shares in the company, valued at approximately $74,039,491.68. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. Also, SVP Michael A. Boxer sold 2,000 shares of the company’s stock in a transaction that occurred on Friday, April 26th. The stock was sold at an average price of $567.94, for a total transaction of $1,135,880.00. Following the sale, the senior vice president now directly owns 13,083 shares of the company’s stock, valued at approximately $7,430,359.02. The disclosure for this sale can be found here. Insiders sold 32,000 shares of company stock worth $18,486,980 in the last quarter. 0.34% of the stock is currently owned by corporate insiders.

Thermo Fisher Scientific Stock Performance

Shares of TMO stock traded down $0.98 during midday trading on Friday, hitting $584.05. 883,271 shares of the company were exchanged, compared to its average volume of 1,282,267. The firm has a market capitalization of $222.94 billion, a P/E ratio of 37.46, a PEG ratio of 2.73 and a beta of 0.80. The company has a debt-to-equity ratio of 0.68, a quick ratio of 1.33 and a current ratio of 1.70. Thermo Fisher Scientific Inc. has a 52 week low of $415.60 and a 52 week high of $603.82. The firm’s 50 day moving average price is $576.44 and its two-hundred day moving average price is $547.49.

Thermo Fisher Scientific (NYSE:TMOGet Free Report) last released its quarterly earnings results on Wednesday, April 24th. The medical research company reported $5.11 earnings per share for the quarter, topping the consensus estimate of $4.70 by $0.41. Thermo Fisher Scientific had a return on equity of 18.45% and a net margin of 14.20%. The business had revenue of $10.35 billion during the quarter, compared to analysts’ expectations of $10.14 billion. As a group, equities research analysts anticipate that Thermo Fisher Scientific Inc. will post 21.65 earnings per share for the current year.

Thermo Fisher Scientific Announces Dividend

The firm also recently declared a quarterly dividend, which will be paid on Monday, July 15th. Investors of record on Friday, June 14th will be given a dividend of $0.39 per share. This represents a $1.56 dividend on an annualized basis and a yield of 0.27%. The ex-dividend date is Friday, June 14th. Thermo Fisher Scientific’s dividend payout ratio is 10.01%.

Wall Street Analyst Weigh In

A number of equities research analysts recently commented on the stock. Raymond James raised their price objective on shares of Thermo Fisher Scientific from $515.00 to $605.00 and gave the stock an “outperform” rating in a report on Thursday, February 1st. JPMorgan Chase & Co. raised their price objective on shares of Thermo Fisher Scientific from $600.00 to $650.00 and gave the stock an “overweight” rating in a report on Thursday, April 25th. Citigroup assumed coverage on shares of Thermo Fisher Scientific in a research report on Monday, March 18th. They issued a “neutral” rating and a $620.00 target price for the company. HSBC lifted their target price on Thermo Fisher Scientific from $660.00 to $670.00 and gave the company a “buy” rating in a research report on Tuesday, April 30th. Finally, Royal Bank of Canada raised their price target on Thermo Fisher Scientific from $592.00 to $642.00 and gave the company an “outperform” rating in a research note on Thursday, February 1st. Five investment analysts have rated the stock with a hold rating and thirteen have given a buy rating to the company. According to MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and an average target price of $605.31.

Read Our Latest Research Report on TMO

Thermo Fisher Scientific Company Profile

(Free Report)

Thermo Fisher Scientific Inc provides life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services in the North America, Europe, Asia-Pacific, and internationally. The company's Life Sciences Solutions segment offers reagents, instruments, and consumables for biological and medical research, discovery, and production of drugs and vaccines, as well as diagnosis of infections and diseases; and solutions include biosciences, genetic sciences, and bio production to pharmaceutical, biotechnology, agricultural, clinical, healthcare, academic, and government markets.

Further Reading

Want to see what other hedge funds are holding TMO? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Thermo Fisher Scientific Inc. (NYSE:TMOFree Report).

Institutional Ownership by Quarter for Thermo Fisher Scientific (NYSE:TMO)

Receive News & Ratings for Thermo Fisher Scientific Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Thermo Fisher Scientific and related companies with MarketBeat.com's FREE daily email newsletter.